Blue Matter will be exhibiting and speaking at The World Evidence, Pricing, and Access (EPA) Congress, 3-4 March 2026 in Amsterdam. Be sure to visit us at booth #514!
This meeting is Europe’s largest congress in market access, pricing, and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from the biopharma industry and payer organizations.
Deepak Veeraraghavan (Partner, London) will be speaking on Tuesday 3 March at 1:00 pm:
From “What If” to “What Matters”: Leveraging Decision Science to Navigate MFN and Global Pricing
As Most Favored Nation (MFN) policies and shifting geopolitical pressures redefine global pricing, the traditional response—limitless, reactive scenario planning—often leads to analysis paralysis rather than strategic advantage. This session proposes a shift toward Value-Focused Thinking. We will outline a methodology for manufacturers, from small-cap companies to global leaders, to first define their “North Star Objectives” (e.g., trade-off between breadth of access, price/value preservation, or strategic corporate priorities such as global health equity). By anchoring in these objectives, teams can filter the noise of global uncertainties to identify the specific scenarios that truly move the needle. Attendees will learn how to use this Decision Science-based approach to identify proactive opportunistic levers, ensuring that strategy is driven by what the organization wants to achieve, rather than just what it fears might happen.
